A PROSPECTIVE, PLACEBO-CONTROLLED STUDY OF THE ANTIANDROGEN CASODEX AS TREATMENT FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

Casodex, a new nonsteroidal antiandrogen, is presently being investiga ted in phase III studies as a new hormonal treatment for advanced pros tatic cancer. The safety and efficacy of Casodex at a dosage of 50 mg. daily for 24 weeks in patients with benign prostatic hypertrophy were investigated in this double-blind placebo-controlled trial, initially planned for 60 patients. Inclusion was discontinued at 30 patients af ter report of liver toxicity when Casodex was given long-term at high doses to mice. Prostate volume was decreased by 26.4% at the end of th erapy (3.7% in the placebo group). The differences between Casodex and placebo therapy for the changes in values from baseline to 24 weeks o f treatment in maximum urinary flow rate at spontaneous micturition an d after instillation of saline were 0.8 and 1.4 ml. per second (not st atistically significant). Pressure-flow examinations and frequency-vol ume charts did not show any treatment effect. Casodex patients tended to obtain more improvement in symptom scores than placebo patients, re aching statistical significance for irritative symptoms at week 24. Ev en if all patients had side effects, mostly mild, Casodex was well tol erated and patient compliance was excellent.